Main Session
Sep
28
PQA 02 - Lung Cancer/Thoracic Malignancies, Patient Reported Outcomes/QoL/Survivorship, Pediatric Cancer
2396 - The Effect of Adding Consolidation Durvalumab to Hypofractionated Involved-Field Radiotherapy with Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: Does Durvalumab Consolidation Therapy Bring Survival Benefits?
Presenter(s)
Tsubasa Kameoka, MD - Miyoshi Central Hospital, Miyoshi city, Hiroshima